The bioinformatics industry in the US merges biology and data science to interpret and manipulate complex biological information. It houses companies that range from genomics and proteomics to software that analyzes biological data for actionable insights. Organizations in this field create tools that enhance research, clinical diagnostics, and personalized medicine by harnessing large datasets. As healthcare trends shift towards data-driven decisions, bioinformatics is poised for growth, driven by advancements in AI and machine learning, and an increasing focus on genomics and personalized medicine. Innovations here are catalyzing breakthroughs, supporting the next generation of medical advancements and therapeutic solutions.

The list features notable bioinformatics investors primarily engaging in venture capital, indicating a strong appetite for innovative startups. Headquartered in major cities like New York and San Francisco, these firms vary in size and history, with many founded in the late 20th century. Investors such as OrbiMed and GV participated in several deals in 2024, indicative of their vigorous activity in nurturing new technologies. The 2024 deal counts underscore their commitment to bioinformatics companies and innovative life science ventures, which cater to growing market demands in healthcare and technology.

Top 19 Bioinformatics Investors in the US

1. OrbiMed

• Website: orbimed.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 1989
• Headcount: 51-200
• Number of deals in 2024: 52
• LinkedIn: orbimed-advisors

OrbiMed is an investment firm based in New York, specializing in healthcare investments since its founding in 1989. With approximately $17 billion in assets under management, OrbiMed focuses on biopharmaceuticals, medical devices, and healthcare services. Notably, they have participated in significant funding rounds for companies in the bioinformatics sector, such as Caris Life Sciences, which raised substantial amounts in both debt and equity financing, and PierianDx, a genomics software firm that raised $30 million with OrbiMed leading the funding. Their investments reflect a commitment to driving innovation in healthcare, particularly in precision medicine and genomics, making them a relevant player in the bioinformatics industry.

2. Y Combinator

• Website: ycombinator.com
• Type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Founded year: 2005
• Headcount: 51-200
• Number of deals in 2024: 802
• LinkedIn: y-combinator

Y Combinator is a prominent startup accelerator and venture capital firm based in San Francisco, California, founded in 2005. It provides funding and mentorship to early-stage technology companies through a structured program that helps entrepreneurs launch and grow their businesses. Y Combinator has successfully launched over 4,000 startups, making it a key player in the technology startup ecosystem. Among its notable investments in the bioinformatics sector are Benchling, which raised $34.5 million in Series C funding to enhance biotech innovations, and Strateos, which raised $8.5 million in Series A funding to advance its automated lab solutions. These transactions highlight Y Combinator's active role in supporting companies that are pushing the boundaries of biotechnology and bioinformatics.

3. Sosv

• Website: sosv.com
• Type: Venture Capital
• Headquarters: United States (USA)
• Founded year: 1995
• Headcount: 51-200
• Number of deals in 2024: 170
• LinkedIn: sosv

SOSV is a venture capital firm founded in 1995, specializing in funding and supporting deep tech startups through its development programs. With a focus on health and climate technology, SOSV provides venture capital investment and resources to help startups grow and succeed. Notably, SOSV has been involved in several funding rounds for BiomeSense, a company developing biosensors and data modeling platforms for clinical applications. In 2019, they participated in a seed funding round for BiomeSense, which raised $2 million to complete its prototype and prepare for clinical trials. Additionally, they have supported BiomeSense in multiple convertible note rounds and seed rounds from 2019 to 2023, showcasing their ongoing commitment to advancing bioinformatics technologies.

4. ARCH Venture Partners

• Website: archventure.com
• Type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Founded year: 1986
• Headcount: 11-50
• Number of deals in 2024: 32
• LinkedIn: arch-venture-partners

ARCH Venture Partners is a venture capital firm based in Chicago, Illinois, founded in 1986. The firm specializes in biotechnology investments, providing funding and strategic support to innovative companies in the life sciences sector. They primarily focus on early-stage biotech firms that are developing groundbreaking medical solutions. Notably, ARCH has been involved in significant transactions within the bioinformatics space, including a $28 million investment in Illumina, a leader in genomic technologies, which has been pivotal in advancing bioinformatics applications. They also participated in funding rounds for Singleron Biotechnologies, which raised $100 million in Series B and $30 million in Series A, focusing on single-cell genomics, a critical area in bioinformatics. Furthermore, their investment in Vizgen, which raised substantial funding in Series C and D rounds, highlights their commitment to supporting companies that are at the forefront of genomic technology development. Overall, ARCH Venture Partners plays a crucial role in advancing bioinformatics through their investments in key players in the industry.

5. Casdin Capital, LLC

• Website: casdincapital.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 2012
• Headcount: 11-50
• Number of deals in 2024: 9
• LinkedIn: casdin-capital-llc

Casdin Capital, LLC is a New York-based venture capital firm founded in 2012, specializing in the life sciences sector. The firm focuses on investing in healthcare, biotechnology, synthetic biology, and technology, providing funding and strategic partnerships to innovative companies. Notably, Casdin Capital has participated in significant funding rounds for companies relevant to bioinformatics, such as SomaLogic, which raised $375 million in post-IPO equity and $121 million in Series A funding, and DNA Script, which raised $165 million in Series C funding. These investments highlight Casdin Capital's commitment to advancing research and development efforts in the life sciences, making them a key player in the bioinformatics landscape.

6. Perceptive Advisors

• Website: perceptivelife.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 1999
• Headcount: 11-50
• Number of deals in 2024: 45
• LinkedIn: perceptive-advisors-llc

Perceptive Advisors is a New York-based venture capital firm founded in 1999, specializing in the life sciences sector. The firm provides capital solutions and investment management services to both private and public healthcare companies, with a focus on biotechnology, pharmaceuticals, and medical devices. Their expertise in the healthcare industry enables them to support innovation and growth effectively. Notably, Perceptive Advisors has been involved in significant transactions within the bioinformatics context, such as leading funding rounds for DNAnexus, which raised $200 million in Series H and $100 million in Series G to enhance its cloud-based clinical testing offerings. Additionally, they participated in a funding round for Metabolon, a precision health firm that raised $72 million to advance its R&D programs in machine learning for biomarker discovery. These investments underscore their active role in the bioinformatics landscape.

7. IndieBio

• Website: indiebio.co
• Type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 76
• LinkedIn: indiebio

IndieBio is a venture capital firm founded in 2015, located in San Francisco, California. It specializes in biotechnology and provides investment, mentorship, and networking opportunities to startups in various sectors, including bioinformatics. IndieBio has been involved in several relevant transactions, such as investing in BiomeSense, which raised $3 million in a seed round in February 2023, and Biomage, which raised $850,000 in a seed round in December 2020. These investments highlight IndieBio's commitment to supporting innovative solutions in the bioinformatics space, making them a key player in the biotechnology investment landscape.

8. GV (Google Ventures)

• Website: gv.com
• Type: Venture Capital
• Headquarters: San Francisco Bay Area, California, United States (USA)
• Founded year: 2009
• Headcount: 51-200
• Number of deals in 2024: 74
• LinkedIn: gv

GV (Google Ventures) is a venture capital firm founded in 2009 and based in the San Francisco Bay Area, California. With over $10 billion in assets under management, GV focuses on providing funding and support to innovative technology startups across various sectors, including life sciences and artificial intelligence. Notably, GV has been actively involved in the bioinformatics space through its investments in DNAnexus, a leading company in cloud-based genomic data analysis. GV participated in multiple funding rounds for DNAnexus, including a $200 million Series H round in March 2022, a $68 million Series F round in February 2019, and several earlier rounds totaling over $270 million. These transactions highlight GV's commitment to advancing bioinformatics technologies and supporting companies that are at the forefront of genomic data analysis and clinical testing.

9. Invus

• Website: invus.com
• Type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Founded year: 1985
• Headcount: 51-200
• Number of deals in 2024: 35
• LinkedIn: invus

Invus is a venture capital investment firm based in New York, specializing in equity investments and investment management since its founding in 1985. The firm partners with owner-managers across various industries to enhance business performance and create sustainable value, focusing on long-term growth. Invus has been actively involved in the bioinformatics sector, notably through its investments in Seer, Inc., which has raised significant funding across multiple rounds (Series B, C, and D) to support its innovative proteomics technology. Additionally, Invus participated in a $110 million funding round for Schrödinger, a company that develops software for drug discovery, which is closely related to bioinformatics. These transactions highlight Invus's engagement in the bioinformatics landscape, showcasing its commitment to supporting advancements in this critical field.

10. Pfizer

• Website: pfizer.com
• Type: Corporate
• Headquarters: New York, New York, United States (USA)
• Founded year: 1849
• Headcount: 10001+
• Number of deals in 2024: 10
• LinkedIn: pfizer

Pfizer Inc. is a leading pharmaceutical and biotechnology company founded in 1849, headquartered in New York, New York, USA. With over 10,000 employees, Pfizer develops and produces a wide range of medicines and vaccines aimed at improving patient health outcomes globally. In recent years, Pfizer has made significant investments in the bioinformatics sector, participating in funding rounds for companies that leverage genomic and transcriptomic technologies. Notably, Pfizer was involved in the Series B and C funding rounds for Strata Oncology, which focuses on genomic analyses for cancer treatment, and they also participated in the Series B funding for CytoReason, a company that utilizes AI and bioinformatics to model human diseases. These investments reflect Pfizer's strategic interest in bioinformatics as a means to enhance drug development and patient care.

11. Foresite Capital

• Website: foresitecapital.com
• Type: Venture Capital
• Headquarters: Larkspur, California, United States (USA)
• Founded year: 2011
• Headcount: 51-200
• Number of deals in 2024: 23
• LinkedIn: foresite-capital-management

Foresite Capital is a venture capital firm based in Larkspur, California, founded in 2011. The firm specializes in healthcare and life sciences, providing funding and strategic support to innovative companies in these sectors. Foresite Capital leverages a data science-driven approach to identify and invest in transformative opportunities. Notably, they have made significant investments in bioinformatics-related companies, including 10X Genomics, which raised $75 million in Series C funding in 2016 and $55.5 million in Series B funding in 2014, and DNAnexus, which raised $200 million in Series H funding in 2022, among other rounds. These transactions highlight Foresite Capital's commitment to advancing technologies that are crucial for the development and commercialization of bioinformatics solutions.

12. Redmile Group

• Website: redmilegroup.com
• Type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Founded year: 2007
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn: redmile-group

Redmile Group is an investment management firm based in San Francisco, California, founded in 2007. The firm specializes in providing asset management and investment strategies to high-net-worth individuals and institutional investors. With a focus on the financial services sector, Redmile Group has made significant investments in the life sciences and biotechnology sectors, particularly in companies that are at the forefront of bioinformatics. Notable transactions include a $100 million investment in PacBio, a leader in genomic sequencing technology, and a $42.5 million investment in Foundation Medicine, which specializes in genomic profiling for cancer. Additionally, their investment in Mammoth Biosciences, which raised $150 million for its innovative diagnostics solutions, further underscores their commitment to advancing bioinformatics and related technologies. Through these investments, Redmile Group demonstrates a strategic interest in supporting the growth of companies that are pivotal to the bioinformatics landscape.

13. Eli Lilly and Company

• Website: lilly.com
• Type: Corporate
• Headquarters: Indianapolis, Indiana, United States (USA)
• Founded year: 1876
• Headcount: 10001+
• Number of deals in 2024: 30
• LinkedIn: eli-lilly-and-company

Eli Lilly and Company is a leading pharmaceutical company based in Indianapolis, Indiana, founded in 1876. The company is dedicated to developing and delivering innovative medicines for various health conditions, including diabetes and cancer. Eli Lilly focuses on improving health outcomes through research initiatives and partnerships. In recent years, they have made strategic investments in bioinformatics-related companies, such as Insilico Medicine, which raised $110 million in a Series E funding round, emphasizing AI and machine learning in drug discovery. They also participated in the Series B funding for Strateos, a company that enhances laboratory automation and data analysis, and in the Series A funding for Lodo Therapeutics, which is involved in drug discovery. These investments highlight Eli Lilly's commitment to integrating bioinformatics into their research and development processes.

14. F-Prime

• Website: fprimecapital.com
• Type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Founded year: 1946
• Headcount: 11-50
• Number of deals in 2024: 39
• LinkedIn: f-prime-capital-partners

F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, founded in 1946. The firm specializes in creating and investing in healthcare and technology companies, providing both venture capital investments and advisory services to entrepreneurs. F-Prime has a global presence and expertise that enables them to effectively support start-ups in developing innovative solutions. Among their notable transactions, F-Prime has invested in Cytek Biosciences, which raised significant funding in multiple rounds (Seed, Series A, and Series B) for its advancements in biosciences technology. Additionally, they participated in the Series A funding of Elucidata, a TechBio company focused on enhancing product capabilities in the bioinformatics space. These investments highlight F-Prime's commitment to supporting companies that are at the intersection of technology and biological research.

15. Janus Henderson Investors

• Website: janushenderson.com
• Type: Private Equity
• Headquarters: Denver, Colorado, United States (USA)
• Founded year: 2017
• Headcount: 1001-5000
• Number of deals in 2024: 39
• LinkedIn: janus-henderson-emea

Janus Henderson Investors is a private equity firm based in Denver, Colorado, founded in 2017. The firm specializes in asset management, offering a diverse range of investment products including ETFs, mutual funds, and managed accounts. With a global presence and a focus on disciplined investment strategies, Janus Henderson serves individual investors, financial professionals, and institutional clients. In the bioinformatics context, Janus Henderson has made notable investments in companies such as SomaLogic, which raised $375 million in post-IPO equity to support its proteomic products, and Parse Biosciences, which secured $50 million in Series C financing to advance its genomic analysis technologies. Additionally, they participated in funding rounds for Element Biosciences, further highlighting their engagement in the bioinformatics and life sciences sectors.

16. Samsara BioCapital

• Website: samsaracap.com
• Type: Venture Capital
• Headquarters: Palo Alto, California, United States (USA)
• Founded year: 2016
• Headcount: 11-50
• Number of deals in 2024: 27
• LinkedIn: samsara-biocapital

Samsara BioCapital is a venture capital firm based in Palo Alto, California, founded in 2016. The firm specializes in biotechnology investments, focusing on innovative therapies and providing support to entrepreneurs in the medical field. Samsara BioCapital offers fundraising and networking guidance to help biotech companies develop and commercialize their products. Notably, they have participated in significant funding rounds for companies relevant to bioinformatics, such as Alamar Biosciences, which raised $80 million in a Series B round, and Ionpath, which closed an $18 million Series B financing round led by Samsara. Their involvement in these transactions highlights their commitment to advancing technologies that are crucial for bioinformatics and healthcare innovation.

17. Khosla Ventures

• Website: khoslaventures.com
• Type: Venture Capital
• Headquarters: Menlo Park, California, United States (USA)
• Founded year: 2004
• Headcount: 51-200
• Number of deals in 2024: 97
• LinkedIn: khosla-ventures

Khosla Ventures is a venture capital firm founded in 2004, based in Menlo Park, California. The firm provides funding and strategic assistance to startups, particularly in technology, healthcare, and sustainability sectors. Khosla Ventures has been actively involved in the bioinformatics space, with significant investments in companies such as Deep Genomics, which raised multiple funding rounds (including Series A, B, and C) to develop AI-driven genetic medicines. Additionally, they invested in Ultima Genomics, a company that has developed innovative genome sequencing technology, highlighting their commitment to advancing bioinformatics and genomics. Khosla Ventures supports entrepreneurs with resources and strategic guidance, helping them navigate the challenges of building their businesses in these cutting-edge fields.

18. Deep Tech Fund (an Alumni Ventures Fund)

• Website: av.vc
• Type: Venture Capital
• Headquarters: Manchester, New Hampshire, United States (USA)
• Founded year: 2023
• Headcount: 51-200
• Number of deals in 2024: 258
• LinkedIn: deep-tech-fund-av-focused-fund

Deep Tech Fund (an Alumni Ventures Fund) is a venture capital firm based in Manchester, New Hampshire, founded in 2023. The fund is part of Alumni Ventures, which connects accredited investors and institutions with high-quality investment opportunities in the startup ecosystem. With a network of over 10,000 investors, the Deep Tech Fund focuses on diversified venture portfolios. Notably, the fund has participated in several significant transactions in the bioinformatics sector, including an investment in Mission Bio, which raised funds for genomic technologies, and Clear Labs, which has raised substantial amounts for its genomic testing solutions. Additionally, their investment in Synteny.Ai highlights their commitment to supporting innovative companies in the bioinformatics and AI-driven analysis space. These transactions demonstrate the fund's active engagement in the bioinformatics industry, making it a relevant player in this field.

19. EcoR1 Capital, LLC

• Website: ecor1cap.com
• Type: Venture Capital
• Headquarters: San Francisco, California, United States (USA)
• Founded year: 2012
• Headcount: 11-50
• Number of deals in 2024: 14
• LinkedIn: ecor1-capital-llc

EcoR1 Capital, LLC is a San Francisco-based venture capital firm founded in 2012, specializing in biotech investments. The firm partners with entrepreneurs to develop innovative therapeutics, focusing on companies that have the potential to improve patient lives. EcoR1 Capital has been involved in several notable transactions in the biotech sector, including investments in Intellia Therapeutics, which focuses on gene editing technologies, and Editas Medicine, a leader in CRISPR technology. Additionally, they participated in Freenome's Series C funding, a company that utilizes AI and bioinformatics for early cancer detection. Their investment strategy emphasizes supporting the development of new medicines, making them a significant player in the biotech landscape, particularly in areas that overlap with bioinformatics.

Bioinformatics Insights: Key Investors in the US

Want to find more investors focusing on the bioinformatics industry?

With Inven, you'll also get to know:

• Deal History: Number of deals and their sizes.
• Portfolio: Companies they've invested in.
• Contact data: Key dealmakers, including their emails and phonenumbers.
• ...and much more!